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Abstract 
 
Collecting duct carcinoma (CDC) is a rare and aggressive form of renal cell carcinoma (RCC) 
arising from the principal cells of the collecting duct.  One third of cases present with 
metastatic disease, but many present in a manner similar to conventional RCC or urothelial 
carcinoma (UC).  We discuss a case of CDC which presented as a small mass at the cortico-
medullary junction, and was discovered at robotic partial nephrectomy (RPN) to be grossly 
involving the collecting system. A 62-year-old man presented with a small renal mass 
suspicious for RCC, which was found on computed tomography (CT) after an episode of 
gross hematuria.  After thorough workup, RPN was attempted; however, intraoperatively the 
mass was found to be involving the collecting system.  Radical nephroureterectomy was 
performed, and the pathology report revealed CDC.  CDC is a rare and aggressive form of 
RCC.  While many cases are metastatic at diagnosis, most patients present with the 
incidental finding of a small renal mass.  There are no reports of a CDC involving the 
collecting system at RPN after negative ureteroscopy preoperatively.  The adjuvant 
therapeutic options for CDC are limited, and long term survival is poor.     
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Introduction 
 
Collecting duct carcinoma (CDC), also 
known as Bellini duct carcinoma, is a rare 
form of renal cell carcinoma (RCC) that 
arises from cells of the collecting duct of 
the kidney.  Although it represents less 
than one percent of all RCC cases (1), CDC 
is particularly aggressive, and up to 32% of 
cases may be metastatic at diagnosis (2).  
Typical presentation is similar to that of 
clear cell RCC (1, 3, 4), though symptoms  
 
from metastatic disease or paraneoplastic 
syndromes at presentation have been 
described (5-7).  
 
We discuss a case of CDC that presented 
as a centrally located renal mass, not 
visible on ureterscopy but eventually found 
to be grossly invading the collecting system 
at the time of partial nephrectomy.  
Included are pathologic images and a 
review of the literature.  
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Ethics approval 
 
The following review of clinical data was 
performed after proper institutional review 
board approval.  
 
Case Report 
 
We present a 62-year-old man with a 
history of hypertension and obesity who 
developed gross hematuria after a fall from 
his bicycle. When the hematuria persisted, 
magnetic resonance imaging (MRI) and 
computed tomography (CT) were 
performed, revealing a 3.6 x 3.2 x 2.5 cm 
left upper pole renal mass (Figure 1 A). 
The mass was mostly endophytic, though 
still present at the cortico-medullary 
junction, so RCC and urothelial carcinoma 
(UC) were both potential diagnoses.  
 
Left retrograde pyelogram and ureteroscopy 
performed one month prior to definitive 
surgery were normal, and selective cytology 
and brush biopsy were both negative for 
malignant cells. Chest CT was negative for 
metastatic disease. Given this workup, 
robotic partial nephrectomy (RPN) was 
performed for presumed endophytic RCC.  
 
The kidney was fully mobilized and the 
main renal artery was clamped, then 
extirpation was attempted. However, upon 
entering the collecting system, the tumor 
was found to be inside the lumen (Figure 1 
B). The immediate concern was for UC, and 
the procedure was converted to a 
nephroureterectomy.  The patient recovered 
from surgery and was discharged from the 
hospital on post-operative day two. 
 
On gross pathologic analysis, a yellow-tan, 
circumscribed and lobulated mass 
measuring 4.2 x 3.5 x 2.7 cm was found in 
the cortico-medullary junction of the upper 
pole.  A pale tan tumor thrombus was 
identified in the renal pelvis, while no 
thrombus was identified in the renal vein.  
On microscopic examination, focal necrosis 
and multiple foci of osseous metaplasia 
were noted (Figure 2).  On 
immunohistochemistry, tumor cells were 
positive for PAX8, focally positive for CA-IX, 
and largely negative for CK903, p63, and 
GATA3.  These findings are consistent with 
collecting duct carcinoma with sarcomatoid 
differentiation.  The tumor was found to be 
invading the renal pelvis, renal cortex and 
perinephric fat; the sinus fat and renal 
vasculature were uninvolved.  Thirty-five 
lymph nodes were removed, and seven were 
found to contain metastatic cancer.  
 
As the patient presently has no signs of 
metastatic disease, he will be followed 
closely with imaging.  Should he suffer 
from recurrence, he will likely undergo 
chemotherapy or combination 
immunotherapy with targeted therapy.  
 
Discussion 
 
We present a rare case of a CDC that 
progressed from noninvasive to collecting 
system invasion within one month.  CDC is 
a form of RCC known for its aggressive 
nature, and is still poorly understood due 
to its rarity.  It is a malignant epithelial 
tumor that is derived from the principal 
cells of the collecting duct of Bellini, which 
is part of the renal collecting system.  This 
is in contrast to the majority of RCCs, 
which are derived from the cells of the 
proximal convoluted tubules of the 
nephron.  This is also distinct from 
urothelial carcinoma (UC), which arises 
from transitional epithelium of the bladder, 
renal pelvis and ureter.  It accounts for 
<1% of all renal malignancies, and can 
affect ages 13-83-years old with a mean 
age of 55 years.  It has a male to female 
ratio of 2:1 (8); 63.3% of patients are white, 
27.5% are African American, and 9.2% are 
other races, according to a large 
retrospective study by Pepek et al. (9).  
 
Potential symptoms at presentation include 
abdominal pain, hematuria, weight loss or 
flank mass; or patients may be 
asymptomatic (3, 4, 8).  Case reports have 
described CDC associated with deep vein 
thrombosis, extensive coagulative necrosis, 
syndrome of inappropriate antidiuretic 
hormone secretion (SIADH) or leukocytosis 
secondary to increased granulocyte-colony 
stimulating factor (G-CSF) production; 
however these cases  are atypical (5, 6).  
About one out of every three patients has 
metastases on presentation, and 
metastases to bone frequently are 
osteoblastic (8).  Our patient presented 
with hematuria but had no signs of 
metastasis.  
Harbin et al.                                                                                                          Collecting duct renal cell carcinoma                                                                                       
Journal of Kidney Cancer and VHL 2015; 2(3):134-139.             http://jkcvhl.com 136 
 
 
 
Figure 1. A, Magnetic resonance imaging (MRI) showing endophytic, posterior upper pole left renal 
mass (indicated by *), suspicious for carcinoma.  B, Intraoperative photograph showing grossly 
invasive mass involving the lumen of the collecting system.  T – Tumor; CS – collecting system; TF – 
tumor fossa. 
 
CDC is a pathologic diagnosis.  The 
diagnosis is made if 1, at least some of the 
lesion involves the medullary region; 2, 
there is a predominant formation of 
tubules; 3, a desmoplastic stromal reaction 
is be present; 4, cytologic features are high 
grade; 5, growth pattern is infiltrative; and 
6, there is an absence of other typical RCC 
subtypes or UC (8).  Differentiation between 
CDC and UC can be challenging, but the 
addition of GATA3 to the 
immunohistochemical profile of p63 and 
PAX8 can help discriminate (10).  
Moreover, a recent study was able to detect 
distinct genetic differences between CDC 
and UC, concluding that CDC indeed has a 
distinct genetic pattern compared to UC.  
This study observed that CDC was 
associated with chromosomal DNA losses 
at 8p, 16p, 1p and 9p and gains in 13q, 
while UC was associated with loss at 9q, 
13q, 8q and gains at 8p (11). 
 
While a pathologic diagnosis is necessary 
for CDC, several studies have focused on 
imaging techniques that may help lead to 
early diagnosis.  A study pooling 18 cases 
of proven CDC documented recurring CT 
findings.  The mean longest diameter of the 
tumor was 6.9 cm and tumors were 
frequently solid, with a medullary location, 
weak or heterogeneous enhancement and 
infiltrative growth.  Vascular invasion only 
occurred in 28% of cases (12).  
Unfortunately, these CT findings are 
nonspecific and cannot differentiate CDC 
from RCC.  
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Figure 2. High magnification photomicrograph showing highly infiltrative carcinoma with tubular 
structure, embedded in desmoplastic stroma.  The tumor cells have eosinophilic cytoplasm 
(arrowhead), the nuclei are large and pleomorphic, with prominent nucleoli (arrow) and coarse 
chromatin.  Also seen is evidence of ossification (*). 
 
 
In our case, UC was suspected given the 
location of the mass on imaging.  However, 
since ureteroscopy and brush biopsy were 
both negative for abnormalities, the 
possibility of RCC involving the collecting 
system was not considered likely.  It is 
speculated that the mass progressed to 
collecting system involvement rapidly after 
ureteroscopy, or that the preoperative 
imaging inadequately characterized the 
mass.  There are no descriptions of this 
clinical scenario in the literature, though 
there is one case of CDC diagnosed by 
positive cytology (13). 
 
The prognosis of CDC is poor as it is an 
aggressive disease, and one third of cases 
are metastatic on presentation (1).  Pepek 
et al. found that three-year survival rates 
for localized, regional and distant disease 
were 93%, 45% and 6% respectively (9).  
Though several treatment options have 
been implemented with some success, a 
standard chemotherapy regimen is not yet 
established due to the rarity of CDC.  
Recently, Dason et al. conducted a 
systematic review of the management of  
 
 
CDC (14).  The authors were able to 
identify three relevant studies, and 
concluded that a gemcitabine-cisplatin or 
gemcitabine-carboplatin regimen offered 
the best response.  
 
Oudard et al. conducted a prospective 
multicenter phase II study evaluating 
gemcitabine-cisplatin/carboplatin in 23 
patients with CDC.  The authors reported a 
26% partial/complete response rate (1 
complete response), while another 10 
patients (44%) experienced disease 
stabilization, and 7 (30%) had disease 
progression (15).  Immunotherapy, in the 
form of interferon (IFN) and interleukin-2 
(IL-2), has been studied and found to be 
ineffective (2, 16).  In a large retrospective 
study of CDC patients from four Japanese 
institutions, there was no response 34 
patients who received IFN or IL-2 (2).  
  
Targeted therapy has also been evaluated 
in several very small trials.  Procopio et al. 
(17) conducted a retrospective study of 
seven patients receiving targeted therapy, 
and identified two patients who lived for 49 
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months (sorafenib then sunitinib) and 19 
months (temsiroliumus, then sunitinib).  
Though several other smaller studies exist 
(18-20), there is simply not enough data to 
provide a definitive answer on the efficacy 
of targeted therapy in CDC.  
 
Conclusion 
 
We present a case of CDC that progressed 
to collecting system invasion in a short 
period of time and required radical 
nephrectomy.  CDC is an aggressive form of 
RCC, associated with low 3-year survival 
and poor response to adjuvant therapy.  
While CDC is rare, it should be considered 
in those cases in which the clinical data 
seem incongruent with the imaging 
findings.  Any surgeon attempting a partial 
nephrectomy should be aware of the 
possibility of surprise collecting system 
involvement, and should be prepared to 
revise the surgical plan as necessary. 
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